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Umesh T Kadam
Summary
Background Heart failure is an important public health issue affecting about 1 million people in the UK, but 
contemporary trends in cause-specific outcomes among different population groups are unknown.
Methods In this retrospective, population-based study, we used the UK Clinical Practice Research Datalink and 
Hospital Episodes Statistics databases to identify a cohort of patients who had a diagnosis of incident heart failure 
between Jan 1, 1998, and July 31, 2017. Patients were eligible for inclusion if they were aged 30 years or older with a 
first code for heart failure in their primary care or hospital record during the study period. We assessed cause-specific 
admission to hospital (ie, hospitalisation) and mortality, by age, sex, socioeconomic status, and place of diagnosis 
(ie, hospital vs community diagnosis).We calculated outcome rates separately for the first year (first-year rates) and for 
the second-year onwards (subsequent-year rates). Patients were followed up until death or study end. This study is 
registered with Clinical Practice Research Datalink Independent Scientific Advisory Committee, protocol number 
18_037R.
Findings We identified 88 416 individuals with incident heart failure over the study period, of whom 43 461 (49%) 
were female. The mean age was 77·8 years (SD 11·3) and median follow-up was 2·4 years (IQR 0·5 to 5·7). 
Age-adjusted first-year rates of hospitalisation increased by 28% for all-cause admissions, from 97·1 (95% CI 
94·3 to 99·9) to 124·2 (120·9 to 127·5) per 100 person-years; by 28% for heart failure-specific admissions, from 
17·2 (16·2 to 18·2) to 22·1 (20·9 to 23·2) per 100 person-years; and by 42% for non-cardiovascular admissions, from 
59·2 (57·2 to 61·2) to 83·9 (81·3 to 86·5) per 100 person-years. 167 641 (73%) of 228 113 hospitalisations were for non-
cardiovascular causes and annual rate increases were higher for women (3·9%, 95% CI 2·8 to 4·9) than for men 
(1·4%, 0·6 to 2·1; p<0·0001); and for patients diagnosed with heart failure in hospital (2·4%, 1·4 to 3·3) than those 
diagnosed in the community (1·2%, 0·3 to 2·2). Annual increases in hospitalisation due to heart failure were 2·6% 
(1·9 to 3·4) for women compared with stable rates in men (0·6%, –0·9 to 2·1), and 1·6% (0·6 to 2·6) for the most 
deprived group compared with stable rates for the most affluent group (1·2%, –0·3 to 2·8). A significantly higher risk 
of all-cause hospitalisation was found for the most deprived than for the most affluent (incident rate ratio 1·34, 
95% CI 1·32 to 1·35) and for the hospital-diagnosed group than for the community-diagnosed group (1·76, 1·73 to 1·80). 
Age-adjusted first-year rates of all-cause mortality decreased by 6% from 24·5 (95% CI 23·4 to 39·2) to 
23·0 (22·0 to 24·1) per 100 person-years. Annual change in mortality was –1·4% (95% CI –2·3 to –0·5) in men but 
was stable for women (0·3%, –0·5 to 1·1), and –2·7% (–3·2 to –2·2) for the community-diagnosed group compared 
with –1·1% (–1·8 to –0·4) in the hospital-diagnosed group (p<0·0001). A significantly higher risk of all-cause mortality 
was seen in the most deprived group than in the most affluent group (hazard ratio 1·08, 95% CI 1·05 to 1·11) and in 
the hospital-diagnosed group than in the community-diagnosed group (1·55, 1·53 to 1·58).
Interpretation Tailored management strategies and specialist care for patients with heart failure are needed to address 
persisting and increasing inequalities for men, the most deprived, and for those who are diagnosed with heart failure 
in hospital, and to address the worrying trends in women.
Funding Wellcome Trust.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Lancet Public Health 2019; 
4: e406–20
See Comment page e365
Diabetes Research Centre, 
University of Leicester, 
Leicester, UK (C A Lawson PhD, 
F Zaccardi PhD, S Ling PhD, 
Prof M J Davies PhD, 
Prof K Khunti PhD, 
Prof U T Kadam PhD); NIHR 
Leicester Biomedical Research 
Centre, Cardiovascular 
Research Centre, Glenfield 
General Hospital, Leicester 
University, Leicester, UK 
(Prof I Squire MD); National 
Heart Centre, Duke-NUS 
Medical School, Singapore 
(Prof C S P Lam PhD); University 
Medical Centre Groningen, 
Groningen, Netherlands 
(Prof C S P Lam); The George 
Institute for Global Health, 
Newton, NSW, Australia 
(Prof C S P Lam); and Keele 
Cardiovascular Research Group, 
Centre for Prognosis Research, 
Keele University, Staffordshire, 
UK (Prof M A Mamas PhD)
Correspondence to: 
Dr Claire A Lawson, Diabetes 
Research Centre, University of 
Leicester, Leicester LE5 4PW, UK 
cl417@leicester.ac.uk
Introduction
Heart failure is a global pandemic affecting approximately 
23 million people worldwide including 6 million people 
in the USA,1 more than 15 million people in Europe, and 
1 million in the UK alone.2,3 Despite improvements in 
heart failure therapies over the past two decades, risk of 
mortality remains high,4 with inequalities reported 
among population groups according to factors such as 
sex and socioeconomic status.5–7 The burden of non-
elective admission to hospital (ie, hospitalisation) is also 
high, accounting for over two-thirds of the estimated 
US$108 billion spent on heart failure globally each year.8 
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Furthermore, the economic costs associated with heart 
failure are likely to increase exponentially over the next 
decade due to a projected 46% increase in the prevalence 
of heart failure by 2030,9 alongside increasing costs of 
health care in an ageing population with multiple 
morbidities. Consequently, attempts to decrease the 
substantial social, health, and economic burden of heart 
failure have become a top public health priority.10
Previous epidemiological evidence in heart failure 
has predominantly focused on mortality in high-risk 
cohorts who have been admitted to hospital,11–13 low-risk 
primary care cohorts,14 or selected communities,5,6,15 
which might not represent the general population of 
people who have heart failure and restrict the potential 
for group comparisons. To develop tailored public 
health prevention approaches and plan health services 
effectively, contemporary population-level data on 
emerging outcome trends among different groups of 
populations with heart failure are required. Information 
on cause-specific rates of hospitalisation in people with 
heart failure is particularly important to meet the 
projected increase in demands. Through linkage of 
primary care, hospital, and mortality data, we investigated 
differences in cause-specific outcomes and trends among 
groups with incident heart failure according to age 
group, sex, socioeconomic status, and place of diagnosis.
Methods
Study design and participants
We used the Clinical Practice Research Datalink (CPRD) 
and Hospital Episodes Statistics (HES) databases to 
identify a cohort of patients in England, UK, with 
incident heart failure diagnosed between Jan 1, 1998, 
and July 31, 2017. The CPRD is one of the largest 
longitudinal, linked, anonymised databases in the world 
and contains approximately 7% of the UK general 
population, representative of the population’s sex and 
age. It includes patient demographics, risk factors, 
symptoms, clinical diagnoses, investigations, referrals, 
and prescriptions and has been validated for epide- 
miological research.16 HES includes all UK National 
Health Service (NHS) admissions in England. The 
Independent Scientific Advisory Committee provided 
permission for data access (protocol identifier 18_037R).
We included all patients aged 30 years or older with a 
first code for heart failure in their primary care or 
hospital record during the 20-year study period. To 
ascertain the diagnostic date of heart failure accurately, 
patients were only included if their CPRD and HES 
records were eligible for linkage (ie, the primary care 
centre had consented to have their records linked) and 
they had been registered with a CPRD primary care 
practice for a minimum of 1 year before heart failure 
Research in context
Evidence before this study
Heart failure affects approximately 23 million people 
worldwide and is associated with adverse clinical outcomes 
(high burden of admissions to hospital, costs, and mortality). 
On Sept 17, 2018, we searched PubMed for observational 
studies published in English since Jan 1, 2000, reporting 
outcome trends in heart failure. We used the term “heart 
failure” in different combinations with “surviv*”, “rate*”, 
“outcome*”, “mortality”, “death*”, “hospital*”, “prognos*”, 
and “trend*”. We reviewed the full text of relevant articles to 
assess appropriateness for inclusion. Most studies were from 
the USA and focused on specific care settings (hospital or 
community) that are unable to ascertain date of incident heart 
failure accurately, or on single communities, which might not 
reflect the general population. No studies had reported on 
cause-specific outcome trends in a national sample of patients 
with incident heart failure, regardless of place of diagnosis, 
among different population groups.
Added value of this study
By linking national general practice, hospital, and death data, 
we were able to report outcome burden after newly diagnosed 
heart failure and make group comparisons. Rates of admission 
to hospital (ie, hospitalisations) are increasing and, although 
mortality has improved slightly over the past 20 years, 
mortality risk is higher than previously reported in 
non-incident cohorts. Furthermore, we found inequities in 
outcomes between different heart failure populations, some of 
which persisted or worsened over time. Risks of all outcomes 
were higher in the older age groups than in the younger age 
groups, for men than for women, the most deprived than for 
the most affluent, and for those first diagnosed with heart 
failure in hospital than those diagnosed in the community. 
We also observed worrying trends for women with heart 
failure, with worsening outcomes over the past two decades. 
By investigating cause-specific outcomes, we showed that 
these disparities probably reflect the growing burden of non-
cardiovascular comorbidities in patients with heart failure, 
requiring contemporary prevention and management 
approaches.
Implications of all the available evidence
In people with heart failure, persisting high mortality and 
increasing hospitalisation rates are a substantial social, 
health, and economic burden. The increasing number of 
people first diagnosed with heart failure in hospital, with 
associated significantly worse outcomes, calls for early 
recognition and timely specialist intervention. Furthermore, 
diverging outcome trends over two decades among 
population groups according to age, sex, socioeconomic 
status, and place of diagnosis calls for tailored public health 
prevention approaches to reduce inequalities and improve 
outcomes for the highest risk groups.
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diagnosis. The date of heart failure diagnosis was the 
date of study entry. We used updated, clinically validated 
heart failure CPRD codes17 and primary International 
Classification of Diseases-10 (ICD-10) discharge codes 
(appendix pp 6–7). If patients had codes in both records, 
the first chronologically was assigned as the date of heart 
failure diagnosis.
Procedures
Patients were categorised into exposure groups defined 
by age (<70 years, 70–79 years, 80–89 years, and 
≥90 years), sex, socioeconomic status, and place of 
diagnosis. Socioeconomic status was based on the 2010 
patient-level Index of Multiple Deprivation score,18 
which was ranked into quintiles (the most affluent 
group [quintile 1] to the most deprived group 
[quintile 5]). Place of diagnosis was defined by where 
the individual had been diagnosed with heart failure, in 
the community or hospital, on the basis of the first 
heart-failure code.
Using the most recent value before study entry, 
we categorised each patient’s baseline characteristics 
associated with heart failure risk including current 
smoking and alcohol (yes or no), body-mass index 
(BMI), systolic blood pressure, cholesterol, haemo- 
globin concentration, and estimated glomerular 
filtration rate (eGFR), which was calculated using the 
Chronic Kidney Disease Epidemiology Collaboration 
formula.19 Prescribed drugs, including β blockers, 
angiotensin-converting enzyme inhibitors, angiotensin 
II receptor blockers, aldosterone receptor antagonists, 
aspirin, and loop diuretics, were identified by at least 
one prescription in a 4-month period before diagnosis 
of heart failure. Comorbidities were identified by at 
least one Read Code in CPRD or ICD-10 code in HES at 
any time up to and including the date of heart failure 
diagnosis.
Outcomes
Our outcomes were cause-specific hospitalisations and 
mortality. Hospitalisations were defined as including all 
non-elective admissions with at least one overnight stay 
and occurring after but not including the date of heart 
failure diagnosis. Overall number of hospitalisations 
during follow-up after heart failure diagnosis were 
counted for each patient and further stratified by the 
following cause-specific admissions: primary heart 
failure, other cardiovascular disease, and non-
cardiovascular disease admissions according to the 
primary discharge code. Date and cause of death was 
ascertained from linked Office of National Statistics 
mortality records. We coded deaths as “cardiovascular” 
when an ICD-10, chapter 9 code was recorded in the 
primary position and “non-cardiovascular disease” for all 
remaining deaths.
For both outcomes follow-up was until death or study 
end (July 31, 2017).
Statistical analysis
Descriptive statistics are presented as number and 
proportion for dichotomous data, mean (SD) for 
continuous data, and median (IQR) for skewed 
continuous data. We did trend analyses in the whole 
group and stratified by age groups, sex, socioeconomic 
status (most affluent quintile, most deprived quintile), 
and place of diagnosis (community, hospital). Given the 
increased risk of poor outcomes in the first year after 
diagnosis of heart failure, we calculated outcome rates 
separately for the first year (first-year rates) and for 
the second year onwards in those who survived their first 
year (subsequent-year rates). Additionally, due to the high 
risk of death in the first month after diagnosis of heart 
failure, we only calculated first-year mortality rates in 
survivors of the first month. We estimated outcome rates 
at the mean population age using age-adjusted negative 
binomial models. We did three trend measurements: 
percentage difference in outcomes rates (measured per 
100 person-years) between two 4-year time periods of 
heart failure diagnosis (1998–2001 and 2012–15) calculated 
as 100*([rate in time period 2 – rate in time period 1]/rate 
in time period 1); average annual percentage change in 
outcome rates; and change in trends using Joinpoint 
regression, which is a statistical software that calculates 
annual percentage change in rate and tests whether any 
apparent change in trend is significant.20 We investigated 
differences in trends between population groups by 
fitting an interaction term (group*year of heart failure 
diagnosis) to the negative binomial models already 
containing age. Because interaction tests have low power, 
we also examined trends visually by plotting graphs of 
outcome rates by year of heart failure diagnosis to aid 
interpretation.
For overall differences between groups, we compared 
each older age group with the youngest age group 
(<70 years; reference), females with males (reference), 
lower socioeconomic quintiles (quintile 2 to 5) with the 
most affluent quintile (quintile 1; reference), and the 
hospital-diagnosed group with the community-diagnosed 
group (reference). We investigated differences in total and 
cause-specific hospitalisation rates among groups using 
negative binomial models to estimate incidence rate ratios 
(IRR) with 95% CIs, presenting unadjusted and adjusted 
for all covariates (ie, age, sex, socioeconomic status, 
ethnicity, place of diagnosis, calendar year of diagnosis, 
β blocker, angiotensin-converting enzyme inhibitor, 
angiotensin receptor blocker, aldosterone antagonist, 
aspirin, loop diuretic, number of comorbidities, ischaemic 
heart disease, myocardial infarction, atrial fibrillation, 
hypertension, diabetes, stroke, anaemia, obesity, 
chronic kidney disease, chronic obstructive pulmonary 
disease, asthma, depression, osteoarthritis, cancer and 
dementia, smoking, alcohol, BMI, systolic blood pressure, 
cholesterol, haemoglobin, and eGFR). For time-to-
mortality outcomes, we used Royston-Parmer flexible 
parametric survival models to do age-standardised survival 
See Online for appendix
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predictions at 1, 3, and 5 years after diagnosis of heart 
failure for the whole group and population subgroups by 
the earliest and latest 4-year time period of diagnosis (ie, 
1998–2001 and 2012–15). Next, we plotted age-standardised 
and calendar-year-standardised survival curves (all-cause 
mortality) and cumulative incidence curves (cause-specific 
mortality).21 Finally, we estimated hazard ratios (HRs), 
unadjusted and adjusted for all covariates, with 95% CIs, 
comparing each subgroup with their respective reference 
group for all-cause and cause-specific death.
To account for missing data in the multivariable 
models ( p 8), we did multiple imputations using 
matching variables and full-conditional specification, 
using the MI Impute command, and results were 
obtained using Rubin’s rules.22 We did sensitivity analyses 
to assess complete-case analysis, in which we removed 
patients for whom missing values had been imputed, 
and stratification of adjusted outcome effects by calendar 
year of diagnosis.
We did all analyses using Stata-MP 14.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data and had final responsibility for the decision to 
submit for publication
Results
We identified 88 416 patients with incident heart failure 
over the 20-year study period, of whom 43 461 (49%) were 
female, with a mean age of 77·8 years (SD 11·3; table 1), 
and a median follow-up time of 2·4 years (IQR 0·5–5·7; 
appendix p 2). Of the study population, 36 415 (41%) 
Predicted first-year rate, per 100 person-years Relative 
difference*
pinteraction† Average annual 
percentage 
change‡
Slope change; annual percentage change before and 
after trend change§
1998–2001 2012–15 Before Break After
All admissions (n=66 664)
All 97·1 (94·3 to 99·9) 124·2 (120·9 to 127·5) 28% ·· 1·8% (1·2 to 2·4) 3·7% (2·4 to 5·2) 2005 0·4% (–0·2 to 1·1)
Age, years
<70 94·1 (88·2 to 100·0) 89·0 (83·9 to 94·0) –5% 1 (ref) –0·2% (–1·2 to 0·8) –0·2% (–1·2 to 0·8) N/A –0·2% (–1·2 to 0·8)
70–79 91·9 (87·4 to 96·3) 107·8 (102·3 to 113·3) 17% <0·0001 0·9% (–0·1 to 2·0) 3·1% (0·8 to 5·4) 2005 –0·6% (–1·7 to 0·6)
80–89 98·4 (93·6 to 103·2) 144·6 (138·3 to 150·8) 47% <0·0001 3·0% (2·4 to 3·7) 6·3% (4·5 to 8·1) 2004 1·3% (0·8 to 1·8)
≥90 102·0 (92·1 to 111·9) 174·1 (161·6 to 186·7) 71% <0·0001 4·4% (2·7 to 6·2) 10·9% (5·8 to 16·3) 2004 1·1% (–0·2 to 2·3)
Sex
Men 109·9 (105·4 to 114·4) 119·1 (114·8 to 123·5) 8% 1 (ref) 0·5% (–0·1 to 1·0) 0·5% (–0·1 to 1·0) N/A 0·5% (–0·1 to 1·0)
Women 85·7 (82·3 to 89·2) 129·7 (124·7 to 134·7) 51% <0·0001 3·0% (2·1 to 3·9) 6·0% (4·3 to 7·7) 2006 0·4% (–0·7 to 1·5)
Socioeconomic status
Most affluent 85·9 (79·8 to 92·1) 109·7 (103·1 to 116·3) 28% 1 (ref) 1·5% (0·0 to 3·1) 4·0% (0·0 to 8·2) 2004 0·2% (–1·1 to 1·5)
Most deprived 113·2 (105·8 to 120·6) 145·3 (135·6 to 155·1) 28% 0·103 1·9% (0·9 to 2·9) 1·9% (0·9 to 2·9) N/A 1·9% (0·9 to 2·9)
Place of diagnosis
Community 80·0 (77·3 to 82·7) 88·3 (84·9 to 91·6) 10% 1 (ref) 0·7% (–0·2 to 1·6) 4·6% (2·2 to 6·9) 2004 –1·3% (–2·1 to –0·5)
Hospital 145·0 (137·6 to 152·5) 163·2 (157·3 to 169·0) 13% 0·058 0·9% (0·3 to 1·5) 0·9% (0·3 to 1·5) N/A 0·9% (0·3 to 1·5)
Heart failure admissions (n=11 543)
All 17·2 (16·2 to 18·2) 22·1 (20·9 to 23·2) 28% ·· 1·8% (0·7 to 2·9) 0·8% (–0·1 to 1·7) 2011 5·2% (0·7 to 9·9)
Age, years
<70 14·5 (12·6 to 16·3) 14·1 (12·5 to 15·7) –3% 1 (ref) –0·5% (–2·7 to 1·9) –6·5% (–10·1 to –2·8) 2015 5·3% (1·7 to 8·9)
70–79 16·4 (14·9 to 17·9) 18·1 (16·3 to 20·0) 10% 0·761 0·1% (–0·9 to 1·0) 0·1% (–0·9 to 1·0) N/A 0·1% (–0·9 to 1·0)
80–89 18·8 (17·1 to 20·6) 26·9 (24·7 to 29·1) 43% <0·0001 2·4% (1·7 to 3·2) 2·4% (1·7 to 3·2) N/A 2·4% (1·7 to 3·2)
≥90 17·8 (14·4 to 21·2) 35·2 (30·4 to 39·9) 98% <0·0001 3·7% (1·4 to 6·0) 3·7% (1·4 to 6·0) N/A 3·7% (1·4 to 6·0)
Sex
Men 20·3 (18·7 to 21·9) 22·4 (20·8 to 24·1) 10% 1 (ref) 0·6% (–0·9 to 2·1) –1·9% (–3·4 to –0·4) 2009 5·3% (1·5 to 9·3)
Women 14·6 (13·4 to 15·8) 21·6 (20·0 to 23·3) 48% <0·0001 2·6% (1·9 to 3·4) 2·6% (1·9 to 3·4) N/A 2·6% (1·9 to 3·4)
Socioeconomic status
Most affluent 15·1 (13·0 to 17·3) 19·1 (16·9 to 21·3) 26% 1 (ref) 1·2% (–0·3 to 2·8) 1·2% (–0·3 to 2·8) N/A 1·2% (–0·3 to 2·8)
Most deprived 20·5 (18·0 to 23·1) 26·2 (22·9 to 29·5) 28% 0·597 1·6% (0·6 to 2·6) 1·6% (0·6 to 2·6) N/A 1·6% (0·6 to 2·6)
Place of diagnosis
Community 11·3 (10·5 to 12·1) 12·3 (11·3 to 13·2) 9% 1 (ref) 0·2% (–0·9 to 1·3) 0·2% (–0·9 to 1·3) N/A 0·2% (–0·9 to 1·3)
Hospital 35·5 (32·2 to 38·7) 32·9 (30·8 to 35·1) –7% 0·403 –1·6% (–3·7 to 0·6) –8·5% (–14·4 to –2·1) 2003 1·4% (–0·5 to 3·4)
(Table 2 continues on next page)
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patients were first diagnosed with heart failure in 
hospital; a proportion that increased exponentially over 
time from 26% in 1998 to 74% in 2017 (appendix p 3).
In the first year after diagnosis of heart failure, 
35 171 (40%) patients had at least one and 15 787 (20%) 
had multiple hospitalisations, resulting in a total of 
66 664 admissions during the first year after heart 
failure diagnosis. First-year rates of hospitalisation 
increased by 28% from 97·1 (95% CI 94·3–99·9) per 100 
person-years during 1998–2001 to 124·2 (120·9–127·5) 
per 100 person-years during 2012–15, but rates began to 
plateau after 2005 (table 2). The steepest increase in 
first-year rates of hospitalisation was among people 
aged 80 years and older with rates for the younger two 
age groups remaining stable. Subsequent-year rates of 
hospitalisation were lower than first-year rates and 
remained stable overall, but with predicted rates 
decreasing over time for the youngest age group and 
increasing over time for the oldest age groups (appendix 
pp 9–11).
Heart failure was listed as the primary cause for 
11 543 (17%) of 66 664 hospitalisations occurring in 
the first year after heart failure diagnosis, and 
16 623 (10%) of 161 449 hospitalisations in subsequent years. 
First-year rates of admission for heart failure increased 
from 17·2 (95% CI 16·2–18·2) per 100 person-years to 
Predicted first-year rate, per 100 person-years Relative 
difference*
pinteraction† Average annual 
percentage 
change‡
Slope change; annual percentage change before and 
after trend change§
1998–2001 2012–15 Before Break After
(Continued from previous page)
Other cardiovascular disease admissions (n=14 776)
All 20·3 (19·3 to 21·3) 22·5 (21·4 to 23·5) 11% ·· 0·7% (–0·4 to 1·8) 5·3% (2·9 to 7·9) 2005 –2·4% (–3·7 to –1·1)
Age, years
<70 23·0 (20·2 to 25·9) 17·8 (15·6 to 20·1) –23% 1 (ref) –1·7% (–2·6 to –0·7) –1·7% (–2·6 to –0·7) N/A –1·7% (–2·6 to –0·7)
70–79 19·9 (18·3 to 21·5) 21·7 (19·8 to 23·6) 9% 0·003 0% (–2·1 to 2·2) 4·5% (–0·2 to 9·3) 2005 –3·0% (–5·5 to –0·4)
80–89 19·0 (17·3 to 20·8) 24·7 (22·6 to 26·8) 30% <0·0001 2·4% (1·2 to 3·7) 10·3% (6·7 to 14·1) 2004 –1·6% (–2·6 to 0·6)
≥90 17·1 (13·6 to 20·6) 27·9 (23·7 to 32·2) 63% <0·0001 3·3% (–0·1 to 6·8) 9·5% (3·7 to 15·7) 2007 –3·4% (–7·9 to 1·4)
Sex
Men 22·6 (21·1 to 24·2) 21·9 (20·5 to 23·3) –3% 1 (ref) –0·1% (–1·8 to 1·6) 5·5% (1·1 to 10·1) 2004 –3·0% (–4·6 to –1·4)
Women 18·2 (16·9 to 19·4) 23·1 (21·6 to 24·7) 27% <0·0001 1·8% (0·4 to 3·2) 6·7% (3·6 to 9·9) 2005 –1·5% (–3·0 to –0·0)
Socioeconomic status
Most affluent 18·6 (16·4 to 20·9) 21·2 (19·0 to 23·4) 14% 1 (ref) 0·8% (–0·8 to 2·5) 7·2% (2·6 to 12·0) 2004 –2·5% (–4·0 to –0·9)
Most deprived 23·0 (20·5 to 25·5) 23·6 (20·8 to 26·3) 3% 0·942 –0·4% (–2·8 to 2·1) 2·9% (0·2 to 5·7) 2008 –4·9% (–9·9 to 0·3)
Place of diagnosis
Community 17·2 (16·2 to 18·3) 18·4 (17·2 to 19·7) 7% 1 (ref) 0·5% (–0·9 to 1·9) 5·9% (2·9 to 9·0) 2005 –3·2 (–4·7 to –1·5)
Hospital 29·3 (26·7 to 31·9) 27·1 (25·4 to 28·8) –8% 0·003 –0·5% (–1·7 to 0·8) 3·2% (–0·0 to 6·6) 2004 –2·5% (–3·7 to –1·2)
Non-cardiovascular disease admissions (n=43 965)
All 59·2 (57·2 to 61·2) 83·9 (81·3 to 86·5) 42% ·· 2·6% (1·9 to 3·3) 4·2% (2·8 to 5·6) 2006 1·2% (0·3 to 2·1)
Age, years
<70 57·1 (51·8 to 62·5) 60·5 (55·0 to 65·9) 6% 1 (ref) 0·6% (–0·9 to 2·2) 0·6% (–0·9 to 2·2) N/A 0·6% (–0·9 to 2·2)
70–79 55·7 (52·5 to 58·9) 72·1 (67·8 to 76·5) 29% 0·006 1·9% (0·9 to 2·8) 3·7% (1·6 to 5·9) 2005 0·6% (–0·4 to 1·6)
80–89 60·0 (56·3 to 63·6) 98·7 (93·4 to 104·0) 65% <0·0001 3·4% (2·8 to 4·0) 3·4% (2·8 to 4·0) N/A 3·4% (2·8 to 4·0)
≥90 66·7 (58·5 to 74·8) 114·7 (103·6 to 125·7) 72% <0·0001 4·2% (2·8 to 5·6) 8·3% (4·9 to 11·8) 2005 1·4% (0·1 to 2·8)
Sex
Men 66·3 (63·1 to 69·6) 79·4 (76·1 to 82·8) 20% 1 (ref) 1·4% (0·6 to 2·1) 1·4% (0·6 to 2·1) N/A 1·4% (0·6 to 2·1)
Women 52·9 (50·4 to 55·5) 88·9 (84·9 to 92·8) 68% <0·0001 3·9% (2·8 to 4·9) 7·1% (5·1 to 9·3) 2006 1·0% (–0·2 to 2·3)
Socioeconomic status
Most affluent 50·9 (46·6 to 55·2) 73·4 (68·3 to 78·6) 44% 1 (ref) 2·2% (1·3 to 3·1) 2·2% (1·3 to 3·1) N/A 2·2% (1·3 to 3·1)
Most deprived 70·0 (64·7 to 75·4) 101·7 (93·9 to 109·5) 45% 0·167 2·8% (1·4 to 4·3) 2·8% (1·4 to 4·3) N/A 2·8% (1·4 to 4·3)
Place of diagnosis
Community 51·6 (49·5 to 53·6) 60·8 (58·1 to 63·5) 18% 1 (ref) 1·2% (0·3 to 2·2) 4·2% (1·6 to 6·8) 2004 –0·4% (–1·2 to 0·5)
Hospital 80·4 (75·4 to 85·3) 109·1 (104·5 to 113·6) 36% <0·0001 2·4% (1·4 to 3·30) 2·4% (1·4 to 3·30) N/A 2·4% (1·4 to 3·30)
Data in parentheses are 95% CIs. With the exception of age groups, all predictions are estimated at the mean population age (77·8 years). Follow-up was until death or study end. N/A=not applicable. 
*Relative percentage difference in admission rates (per 100 person-years) between the first and second diagnosis time periods. †p value for the difference in interaction between calendar year and group. 
‡Average annual percentage change in rates (per 100 person-years) for each increasing year of diagnosis. §Change in slope estimated using Joinpoint regression.
Table 2: Predicted rates of hospitalisation during the first year after heart failure diagnosis, by population group and calendar year
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22·1 (20·9–23·2) per 100 person-years, at an average 
increase of 1·8% per annum (table 2), whereas subsequent-
year rates remained stable (appendix pp 9–11). This steady 
increase was in contrast with first-year hospitalisations due 
to other cardiovascular disease, which decreased by 
2·4% per annum after 2005 (table 2). Patterns in first-year 
rates of hospitalisation by cause of admission, population 
group, and year are shown in figure 1. Of 228 113 total 
hospitalisations, non- cardiovascular events were the 
predominant cause (n=167 641 [73%]), with first-year rates 
increasing from 59·2 (95% CI 57·2–61·2) per 100 person-
years to 83·9 (81·3–86·5) per 100 person-years, an average 
increase of 2·6% per annum (table 2). Subsequent-year 
rates were also high and increased by 0·8% per annum, 
reaching 64·0 (95% CI 62·3–65·8) per 100 person-years 
during 2012–15 (appendix pp 9–11).
During follow-up, 65 063 (74%) patients died, 
with 32 623 (50%) due to cardiovascular events and 
32 440 (50%) due to non-cardiovascular disease events. 
During 1998–2001, 2397 (14%) of 17 550 patients died 
during the first month after heart failure diagnosis, 
whereas during 2012–15 this number decreased to 1967 
(11%) of 17 834 patients (table 3). In those who survived 
the first month after their diagnosis of heart failure, age-
adjusted first-year mortality rates decreased slightly 
from 24·5 (95% CI 23·4–25·7) per 100 person-years to 
23·0 (22·0–24·1) per 100 person-years, but differences 
were seen by age (table 3). The youngest two age groups 
Figure 1: Predicted rates of cause-specific hospitalisation during the first year after heart failure diagnosis, by population group
Data are predicted hospitalisation rates, estimated at the mean population age (77·8 years), per 100 person-years by cause, between 1998 and 2015. Whiskers are 95% CIs. Hospitalisations included all 
non-elective admissions with at least one overnight stay and occurring after but not including the date of heart failure diagnosis. Follow-up was until death or study end.
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had decreases in mortality whereas the oldest groups had 
a significant increase in mortality. In the group aged 
90 years and older, mortality increased by 20%, reaching 
69·6 (95% CI 63·2–76·0) per 100 person-years in 2012–15 
(table 3). First-year rates of mortality by calendar year and 
population group are shown in figure 2. Subsequent-year 
rates of mortality were lower than first-year rates and 
decreased by 16% over time, reaching 14·7 (95% CI 
14·3–15·2) per 100 person-years in 2012–15 (table 3). 
Between 1998–2001 and 2012–15, age-standardised 
mortality risk after heart failure diagnosis decreased 
from 32% to 29% at 1 year, from 50% to 46% at 3 years, 
and from 63% to 59% at 5 years (appendix p 12).
During 1998–2001, age-adjusted first-year and 
subsequent-year rates of all-cause and cause-specific 
hospitalisations were higher for men than for women 
(tables 1 and 2). However, by 2012–15, first-year rates for 
all-cause hospitalisations were significantly higher in 
women than in men (p<0·0001), explained by increasing 
rates for women and stable rates in men (table 2, figure 1). 
First month all-cause 
deaths
Predicted first-year mortality, per 100 
person-years
Relative 
difference*
pinteraction† Average annual 
percent change‡
Slope change; annual percent change before and 
after break§
1998–2001 
(n=17 550)
2012–15 
(n=17 834)
1998–2001 2012–15 Before Break After
First-year rates ¶
All 2397 (14%) 1967 (11%) 24·5 (23·4 to 25·7) 23·0 (22·0 to 24·1) –6% ·· –0·5% (–0·9 to –0·2) –0·5% (–0·9 to –0·2) N/A –0·5% (–0·9 to –0·2)
Age, years
<70 328 (10%) 186 (5%) 13·6 (12·1 to 15·1) 8·9 (7·9 to 10·0) –35% 1 (ref) –3·6% (–4·9 to –2·3) –3·6% (–4·9 to –2·3) N/A –3·6% (–4·9 to –2·3)
70–79 684 (11%) 301 (7%) 21·8 (20·2 to 23·4) 15·8 (14·4 to 17·3) –28% 0·113 –2·3% (–3·0 to –1·6) –2·3% (–3·0 to –1·6) N/A –2·3% (–3·0 to –1·6)
80–89 1004 (16%) 901 (13%) 32·6 (30·4 to 34·8) 34·1 (31·9 to 36·3) 5% <0·0001 0·3% (–0·1 to 0·8) 0·3% (–0·1 to 0·8) N/A 0·3% (–0·1 to 0·8)
≥90 381 (21%) 579 (22%) 58·1 (51·5 to 64·7) 69·6 (63·2 to 76·0) 20% <0·0001 1·2% (0·0 to 2·4) 1·2% (0·0 to 2·4) N/A 1·2% (0·0 to 2·4)
Sex
Men 1103 (13%) 926 (10%) 29·2 (27·4 to 31·0) 23·5 (22·1 to 24·9) –20% 1 (ref) –1·4% (–2·3 to –0·5) –2·6% (–3·4 to –1·7) 2009 0·8% (–1·7 to 3·3)
Women 1294 (14%) 1041 (12%) 20·7 (19·5 to 22·0) 22·0 (20·7 to 23·4) 6% <0·0001 0·3% (–0·5 to 1·1) 0·3% (–0·5 to 1·1) N/A 0·3% (–0·5 to 1·1)
Socioeconomic status
Most 
affluent
375 (13%) 367 (10%) 23·8 (21·3 to 26·2) 21·1 (19·1 to 23·1) –11% 1 (ref) –0·8% (–1·2 to –0·4) –0·8% (–1·2 to –0·4) N/A –0·8% (–1·2 to –0·4)
Most 
deprived
476 (14%) 310 (11%) 27·6 (24·8 to 30·4) 25·7 (22·9 to 28·5) –7% 0·46 –0·2% (–1·2 to 0·8) –0·2% (–1·2 to 0·8) N/A –0·2% (–1·2 to 0·8)
Place of diagnosis
Community 1449 (11%) 606 (7%) 20·8 (19·7 to 21·8) 14·2 (13·2 to 15·1) –32% 1 (ref) –2·7% (–3·2 to –2·2) –2·7% (–3·2 to –2·2) N/A –2·7% (–3·2 to –2·2)
Hospital 948 (19%) 1361 (15%) 38·8 (35·8 to 41·8) 34·3 (32·3 to 36·2) –12% <0·0001 –1·1% (–1·8 to –0·4) –1·1% (–1·8 to –0·4) N/A –1·1% (–1·8 to –0·4)
Subsequent-year rates||
All 5475 (31%) 5143 (29%) 17·6 (17·3 to 18·0) 14·7 (14·3 to 15·2) –16% ·· –1·3% (–1·6 to –1·1) –1·3% (–1·6 to –1·1) N/A –1·3% (–1·6 to –1·1)
Age, years
<70 682 (20%) 479 (13%) 8·0 (7·7 to 8·4) 5·4 (4·9 to 5·9) –33% 1 (ref) –2·9% (–3·6 to –2·1) –2·9% (–3·6 to –2·1) N/A –2·9% (–3·6 to –2·1)
70–79 1638 (27%) 872 (19%) 14·6 (14·1 to 15·0) 11·3 (10·5 to 12·0) –23% 0·001 –1·9% (–2·2 to –1·6) –1·9% (–2·2 to –1·6) N/A –1·9% (–2·2 to –1·6)
80–89 2274 (36%) 2363 (35%) 23·7 (23·0 to 24·5) 20·8 (19·8 to 21·7) –12% <0·0001 –0·9% (–1·3 to –0·6) –0·9% (–1·3 to –0·6) N/A –0·9% (–1·3 to –0·6)
≥90 881 (49%) 1429 (54%) 38·3 (35·8 to 40·8) 41·7 (38·8 to 44·7) 9% <0·0001 0·4% (–0·1 to 1·0) 0·4% (–0·1 to 1·0 N/A 0·4% (–0·1 to 1·0
Sex
Men 2630 (31%) 2501 (27%) 20·2 (19·6 to 20·7) 15·1 (14·4 to 15·8) –25% 1 (ref) –2·2% (–2·5 to –1·9) –2·2% (–2·5 to –1·9) N/A –2·2% (–2·5 to –1·9)
Women 2845 (31%) 2642 (31%) 15·8 (15·4 to 16·2) 14·2 (13·5 to 14·8) –10% <0·0001 –0·8% (–1·1 to –0·5) –0·8% (–1·1 to –0·5) N/A –0·8% (–1·1 to –0·5)
Socioeconomic status
Most 
affluent
908 (31%) 1000 (28%) 16·2 (15·5 to 16·9) 13·1 (12·2 to 14·0) –19% 1 (ref) –1·4% (–2·1 to –0·7) –1·4% (–2·1 to –0·7) N/A –1·4% (–2·1 to –0·7)
Most 
deprived
1056 (32%) 782 (29%) 20·2 (19·4 to 21·1) 16·9 (15·5 to 18·2) –16% 0·60 –1·3% (–1·8 to –0·9) –1·3% (–1·8 to –0·9) N/A –1·3% (–1·8 to –0·9)
Place of diagnosis
Community 3452 (27%) 1656 (19%) 16·7 (16·3 to 17·1) 12·0 (11·5 to 12·5) –28% 1 (ref) –2·4% (–2·7 to –2·1) –2·4% (–2·7 to –2·1) N/A –2·4% (–2·7 to –2·1)
Hospital 2023 (31%) 3487 (38%) 21·4 (20·6 to 22·2) 18·7 (17·9 to 19·5) –13% <0·0001 –1·0% (–1·3 to –0·7) –1·0% (–1·3 to –0·7) N/A –1·0% (–1·3 to –0·7)
Crude mortality in the first month after heart failure diagnosis is reported as n (%), with the denominator being the number of people diagnosed during that time period. Estimates have 95% CIs in parentheses. 
With the exception of age groups, all predictions are estimated at the mean population age (77·8 years). N/A=not applicable. *Relative percentage difference in mortality (per 100 person-years) between the first 
and second diagnosis calendar time periods. †p value for the difference in trend lines between groups. ‡Average annual percentage change in rates (per 100 person-years) for each increasing year of diagnosis. 
§Change in slope estimated using Joinpoint regression. ¶Among those who survived the first month after diagnosis. ||Among those who survived the first year after diagnosis.
Table 3: Predicted mortality after heart failure diagnosis, by population group and calendar year
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Also, the first-year rates of non-cardiovascular disease 
hospitalisation increased twice as much among women 
(3·9% per annum) than among men (1·4% per annum; 
table 2). Similar patterns were found for subsequent-year 
rates (appendix pp 9–11). After full covariate adjustment, 
women had a lower IRR for all cause-specific 
hospitalisation than men did, with the largest decrease 
seen for cardiovascular disease hospitalisations (table 4). 
However, when stratified by year of diagnosis, these risk 
differences lessened and became non-significant in 
later years (data not shown).
In 1998–2001, first-year rates of mortality were higher 
for men than for women but the gap between the sexes 
decreased by 2012–15 (table 3). This decrease in the gap 
was due to a 2·6% per annum decrease in mortality for 
men until 2009, which stabilised thereafter, compared 
with stable mortality for women throughout the study 
period (table 3, figure 2). Subsequent-year rates of 
mortality decreased at twice the rate in men (–2·2% per 
annum) as in women (–0·8% per annum; table 3). 
Overall, age-standardised mortality risk at 1, 3, and 
5 years after diagnosis was approximately 3–4% higher 
in men than in women, which persisted throughout 
the study period (appendix p 12). Before adjustment, 
mortality risk was higher in women than in men; 
however, after full adjustment, women were at lower risk 
than men of all-cause mortality, and cardiovascular 
disease and non-cardiovascular disease deaths (table 5; 
Figure 2: First-year rates of mortality, by population group and calendar year of diagnosis
Data are predicted rates of mortality per 100 person-years at mean population age (77·8 years) per 100 person-years 
between 1998 and 2015. Whiskers are 95% CIs. Rates were calculated in survivors of the first month after heart 
failure diagnosis.
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Total 
admissions
Follow-up, person-years Cause of hospitalisation
Total Median (IQR) All-cause Cardiovascular disease Non-cardiovascular disease
Unadjusted IRR Adjusted IRR* Unadjusted IRR Adjusted IRR* Unadjusted IRR Adjusted IRR*
All 228 113 330 137 2·4 (0·5–5·7) ·· ·· ·· ·· ·· ··
Age, years
<70 57 164 106 267 4·8 ( 1·6–9·2) 1·0 (ref) 1·0 (ref) 1·0 (ref) 1·0 (ref) 1·0 1·0
70–79 77 526 115 053 3·3 (0·9–6·9) 1·31 (1·27–1·34) 1·21 (1·18–1·24) 1·29 (1·24–1·34) 1·18 (1·13–1·23) 1·31 (1·27–1·35) 1·23 (1·20–1·27)
80–89 76 565 91 903 1·8 (0·3–4·2) 1·64 (1·60–1·68) 1·47 (1·43–1·51) 1·65 (1·59–1·71) 1·45 (1·39–1·52) 1·64 (1·59–1·68) 1·49 (1·45–1·54)
≥90 16 858 16 914 0·7 (0·1–2·3) 1·94 (1·87–2·01) 1·72 (1·65–1·79) 1·89 (1·79–1·99) 1·67 (1·57–1·77) 1·95 (1·88–2·03) 1·74 (1·67–1·82)
Sex
Male 116 829 174 160 2·5 (0·5–5·9) 1·0 (ref) 1·0 (ref) 1·0 (ref) 1·0 (ref) 1·0 (ref) 1·0 (ref)
Female 111 284 155 977 2·2 (0·4–5·4) 1·05 (1·03–1·07) 0·91 (0·90–0·92) 0·97 (0·94–1·00) 0·85 (0·83–0·88) 1·09 (1·07–1·11) 0·90 (0·88–0·92)
Socioeconomic status
Quintile 1 (most affluent) 37 567 62 395 2·4 (0·5–5·8) 1·0 (ref) 1·0 (ref) 1·0 (ref) 1·0 (ref) 1·0 (ref) 1·0 (ref)
Quintile 2 50 412 76 813 2·4 (0·5–5·7) 1·08 (1·05–1·11) 1·05 (1·02–1·08) 1·10 (1·05–1·15) 1·06 (1·02–1·11) 1·08 (1·04–1·11) 1·05 (1·02–1·08)
Quintile 3 47 541 70 313 2·3 (0·4–5·7) 1·13 (1·10–1·17) 1·10 (1·07–1·13) 1·14 (1·09–1·19) 1·10 (1·05–1·15) 1·13 (1·09–1·17) 1·09 (1·06–1·12)
Quintile 4 48 043 65 182 2·4 (0·4–5·6) 1·20 (1·16–1·23) 1·14 (1·11–1·18) 1·16 (1·11–1·22) 1·12 (1·08–1·17) 1·22 (1·18–1·26) 1·16 (1·12–1·19)
Quintile 5 
(most deprived)
44 228 54 986 2·3 (0·4–5·6) 1·34 (1·32–1·35) 1·20 (1·17–1·24) 1·23 (1·17–1·29) 1·18 (1·13–1·19) 1·33 (1·28–1·37) 1·22 (1·21–1·25)
Place of diagnosis 
Community 135 050 234 304 3·3 (0·9–6·9) 1·0 (ref) 1·0 (ref) 1·0 (ref) 1·0 (ref) 1·0 (ref) 1·0 (ref)
Hospital 93 063 95 833 1·3 (0·2–3·8) 1·76 (1·73–1·80) 1·52 (1·49–1·55) 2·04 (1·98–2·10) 1·77 (1·72–1·82) 1·64 (1·63–1·66) 1·40 (1·37–1·43)
Data are n, person-years, median (IQR), or IRR (95% CI). IRR=incidence rate ratio. *Adjusted for all covariates. 
Table 4: Association between population group and hospitalisation
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appendix p 4). Again, after stratifying by year of 
diagnosis, the difference between the sexes was 
attenuated, becoming non-significant by 2016 (data 
not shown).
In 1998–2001, first-year rates of any-cause 
hospitalisation were significantly higher in the most 
deprived socioeconomic group (quintile 5) than in the 
most affluent group (quintile 1; table 2). This difference 
persisted over time due to similar increasing rates of 
hospitalisation in both groups (p=0·103 for interaction of 
trend lines; table 2, figure 1) and subsequent-year rates 
showed a similar pattern (appendix pp 9–11). In the most 
recent time period (2012–15), the biggest difference 
between the most affluent and most deprived groups was 
for first-year rate of hospitalisation for non-cardiovascular 
disease (table 2). In the fully adjusted model, the most 
deprived group had a significantly higher risk than the 
most affluent group of all-cause, cardiovascular disease, 
and non-cardiovascular disease hospitalisation (table 4). 
Risk increased with quintiles of socioeconomic status 
from the highest (quintile 1) to the lowest quintile 
(quintile 5; table 4).
In 2012–15, first-year rates of mortality were higher in 
the most deprived group than in the most affluent group 
(table 3, figure 2). Age-standardised mortality risk 
increased for each quintile of socioeconomic status, from 
the most affluent to the most deprived group: in 2012–15, 
for quintile 1 versus quintile 5, mortality risk was 27% 
versus 32% at 1 year after diagnosis, 43% versus 50% at 
3 years after diagnosis, and 56% versus 63% at 5 years 
after diagnosis (appendix p 12). After full adjustment, the 
most deprived group still had a higher risk than the most 
affluent group of all-cause, cardiovascular disease, and 
non-cardiovascular disease death (table 5), and age-
standardised survival decreased for each quintile of 
socioeconomic status (appendix p 4).
First-year rates of any-cause hospitalisation were 
significantly higher in the hospital-diagnosed group than 
in the community-diagnosed group, with similar growth 
over time (table 2). Annual rates of admission between 
the two groups began to diverge after 2004, decreasing at 
the same rate for the community group as they increased 
for the hospital group (–1·3% and 0·9% per annum; 
table 2, figure 1). The hospital group had a consistent 
2·4% per annum increase in first-year rate of non-
cardiovascular disease hospit alisation, whereas first-year 
rates did not increase for the community group after 2004 
(table 2). When adjusted for all covariates, the hospital-
diagnosed group had significantly higher risk than the 
community-diagnosed group of hospitalisation due to all-
causes, cardiovascular disease and non-cardiovascular 
disease (table 4).
Total deaths Mean 
survival 
time, years
Median 
age at 
death, 
years
Cause of death
All-cause Cardiovascular disease Non-cardiovascular disease
Unadjusted HR Adjusted HR* Unadjusted HR Adjusted HR* Unadjusted HR Adjusted HR*
All 65 063 (74%) 3·2 (3·1–3·2) 84 (78–90) ·· ·· ·· ·· ·· ··
Age, years
<70 8859 (49%) 9·0 (8·8–9·3) 67 (62–71) 1·0 (ref) 1·0 (ref) 1·0 (ref) 1·0 (ref) 1·0 (ref) 1·0 (ref)
70–79 18 517 (72%) 4·5 (4·5–4·6) 79 (76–82) 1·88 (1·84–1·93) 1·68 (1·64–1·73) 1·77 (1·70–1·83) 1·60 (1·54–1·66) 2·00 (1·93–2·08) 1·73 (1·66–1·81)
80–89 27 568 (83%) 2·2 (2·1–2·2) 87 (84–89) 3·27 (3·19–3·36) 2·66 (2·58–2·74) 3·15 (3·04–3·26) 2·59 (2·49–2·70) 3·33 (3·20–3·46) 2·61 (2·49–2·73)
≥90 10 119 (90%) 0·8 (0·8–0·9) 94 (92–96) 5·59 (5·42–5·76) 4·08 (3·93–4·22) 5·30 (5·08–5·52) 3·95 (3·76–4·15) 5·84 (5·57–6·12) 4·05 (3·82–4·29)
Sex
Male 31 819 (71%) 3·5 (3·4–3·5) 82 (75–88) 1·0 (ref) 1·0 (ref) 1·0 (ref) 1·0 (ref) 1·0 (ref) 1·0 (ref)
Female 33 244 (76%) 2·9 (2·8–2·9) 86 (80–91) 1·15 (1·13–1·17) 0·85 (0·83–0·86) 1·11 (1·09–1·13) 0·85 (0·83–0·88) 1·21 (1·18–1·24) 0·84 (0·82–0·87)
Socioeconomic status
Quintile 1 (most 
affluent)
11 645 (71%) 3·4 (3·3–3·5) 86 (80–90) 1·0 (ref) 1·0 (ref) 1·0 (ref) 1·0 (ref) 1·0 (ref) 1·0 (ref)
Quintile 2 15 093 (74%) 3·2 (3·3–3·5) 85 (79–90) 1·05 (1·03–1·08) 1·05 (1·03–1·08) 1·07 (1·04–1·11) 1·09 (1·05–1·12) 1·02 (0·98–1·06) 1·01 (0·97–1·05)
Quintile 3 14 065 (74%) 3·1 (3·0–3·2) 85 (89–90) 1·07 (1·04–1·10) 1·07 (1·05–1·10) 1·11 (1·07–1·15) 1·12 (1·09–1·16) 1·03 (1·00–1·08) 1·02 (0·98–1·06)
Quintile 4 12 971 (74%) 3·1 (3·0–3·2) 84 (77–89) 1·06 (1·04–1·09) 1·11 (1·09–1·14) 1·06 (1·02–1·10) 1·12 (1·09–1·17) 1·06 (1·02–1·11) 1·10 (1·06–1·14)
Quintile 5 (most 
deprived)
11 149 (75%) 3·1 (2·9–3·2) 82 (75–88) 1·08 (1·05–1·11) 1·17 (1·14–1·21) 1·06 (1·02–1·10) 1·18 (1·14–1·23) 1·12 (1·07–1·16) 1·17 (1·13–1·22)
Place of diagnosis
Community 37 734 (73%) 4·2 (4·2–4·3) 84 (78–90) 1·0 (ref) 1·0 (ref) 1·0 (ref) 1·0 (ref) 1·0 (ref) 1·0 (ref)
Hospital 27 329 (75%) 1·9 (1·8–1·9) 85 (78–90) 1·55 (1·53–1·58) 1·46 (1·43–1·48) 1·72 (1·69–1·76) 1·55 (1·51–1·59) 1·28 (1·25–1·31) 1·37 (1·34–1·40)
Data are n (%), mean (95% CI), median (IQR), and HR (95% CI). HR=hazard ratio. *Adjusted for all covariates.
Table 5: Associations between population groups and mortality
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First-year rates of mortality in the hospital-diagnosed 
group were nearly double the rates in the community-
diagnosed group in 1998–2001, and this gap widened 
over time to 2012–15 (p<0·0001). Age-adjusted first-year 
rates of mortality decreased in the community-diagnosed 
group (–2·7% per annum) at twice the rate of the 
hospital-diagnosed group (–1·1% per annum; table 3, 
figure 2). A similar pattern was identified for subsequent-
year rates (table 3). Over the study period, first-year 
mortality risk in the hospital-diagnosed group was 36% 
whereas it was 27% in the community-diagnosed 
group. During 2012–15, age-standardised mortality risk 
remained significantly higher in the hospital-diagnosed 
group than in the community-diagnosed group: 1 year 
(34% vs 24%), 3 years (53% vs 40%), and 5 years after 
diagnosis (66% vs 52%; appendix p 12). Overall, median 
survival time in the community-diagnosed group was 
twice that of the hospital-diagnosed group (table 5; 
appendix p 4). In the fully adjusted models, the hospital-
diagnosed group had significantly higher risk than the 
community-diagnosed group of all-cause, cardiovascular 
disease, and non-cardiovascular disease deaths (table 5).
For all groups, risk of cardiovascular death was higher 
than non-cardiovascular disease deaths for the first 
few years after diagnosis of heart failure, but the two 
causes converged in later years with non-cardiovascular 
disease causes of death being the most common cause of 
death at around 3–5 years (appendix p 5). In our 
sensitivity analysis, effects remained relatively stable 
after full-case analysis (appendix p 13).
Discussion
Our study provides a comprehensive and contemporary 
assessment of outcomes in patients with incident heart 
failure who were diagnosed with heart failure in hospital 
and community settings. In a large, nationally 
representative sample over 20 years, we identified specific 
diverging trends and inequalities in admission to hospital 
and mortality in the UK. Non-elective hospitalisation 
burden has increased, particularly for non-cardiovascular 
disease causes, which account for over two-thirds of all 
admissions. Heart failure remains associated with a high 
risk of death, with only minimal improvement in risk 
over the past 20 years. Inequalities and poor outcomes 
have persisted, particularly for the oldest age groups, 
men, the most deprived, and for patients diagnosed in 
hospital, and new worrying trends for women have 
emerged.
Mortality risk after a diagnosis of heart failure has 
decreased slightly over the past two decades; whereas 
1-year and 5-year mortality risk has decreased by 3–4%. 
This small decrease is probably in part because of 
advances in diagnostic technology to identify milder 
heart failure. Despite the decrease in risk, our 1-year and 
5-year figures are similar or worse than those in 2000 in 
the Framingham23 (29% at 1 year) and Rochester24 (48% at 
5 years) cohorts. Hospital cohorts in the USA,11 
Scotland,25 and Demark26 reported slightly lower 1-year 
risks (29% in the USA, 33% in Scotland, and 30% in 
Denmark) than the 34% risk in our hospital-diagnosed 
group. Similarly, community cohorts from the UK14 have 
reported 1-year mortality risk of 24% compared with the 
27% overall 1-year mortality risk in our community-
diagnosed group. Like most epidemiological evidence 
on heart failure from hospital-only or primary care-only 
cohorts, these cohort studies were not able to ascertain 
the date of heart failure diagnosis. By linking community 
and hospital records, we were able to identify the date of 
incident heart failure, which probably accounts for the 
higher risk of mortality in our study and indicates that 
the true risk burden for patients with heart failure might 
be higher than previously reported. The persisting high 
risk associated with heart failure possibly reflects the 
ageing multimorbid population, alongside a survival 
plateau in the era of effective, evidence-based treatment 
for heart failure (selective β blockers and angiotensin-
converting enzyme inhibitors). The increase in the 
number of admissions to hospital due to non-
cardiovascular disease events and that 50% of deaths 
were due to non-cardiovascular disease events would 
support this hypothesis.
We observed a new and important pattern of increasing 
hospitalisation due to heart failure. Previous evidence on 
cause-specific patterns grouped admissions due to heart 
failure with cardiovascular admissions, reporting stable 
or decreasing rates over time.5 By partitioning out heart 
failure from other cardiovascular admissions, we found a 
new pattern that has not previously been reported. This 
finding is particularly important given the increase in the 
number of outpatient units that should reduce the 
number of patients with acute heart failure who need to 
be admitted to hospital, meaning that our findings might 
underestimate the worsening problem of acute heart 
failure. Increased hospitalisation due to heart failure was 
particularly pronounced in women and possibly indicates 
later presentation of more severe heart failure in older 
multimorbid patients than would be seen in men. Other 
potential triggers might be a lack of evidence-based 
therapies for heart failure with preserved ejection 
fraction, which is increasing in prevalence,27 or improved 
survival of patients with severe heart failure with 
contemporary therapies for heart failure.
Patients who had hospital-diagnosed heart failure had 
significantly worse outcome rates over time compared 
with the community-diagnosed group; a finding shared 
by previous reports.28,29 Our findings reveal an exponential 
increase in the number of patients diagnosed with heart 
failure in hospital, accounting for 74% of the population 
admitted for heart failure by 2017. Furthermore, our study 
showed that the steeply increasing burden of non-
cardiovascular disease hospitalisations were pre-
dominantly in the hospital-diagnosed group. Mortality 
was also significantly higher for the hospital-diagnosed 
group than for the community-diagnosed group, with 
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slower rates of decrease than in the community-
diagnosed group. Delayed diagnosis, higher comorbidity 
burden, and lower pres- cribing of first-line preventive 
medications, leading to more severe heart failure at the 
point of diagnosis, might in part explain the worse 
prognosis in this group than in the community-
diagnosed group. The 2018 UK National Heart Failure 
Audit30 suggests that an increase in dedicated heart 
failure specialists results in better outcomes for patients 
who have been admitted to hospital and policy 
recommends that all patients with heart failure have 
access to a multidisciplinary team.31 Notably, evidence-
based treatments for heart failure are relevant only to 
those with decreased ejection fraction, and some of the 
apparent under-use of these treatments might be 
explained by a lack of evidence for the use of these 
treatments in patients with heart failure with preserved 
ejection fraction. A 2018 report showed that around half 
of patients who are diagnosed in hospital present earlier 
to their primary care physician with heart failure 
symptoms,32 indicating that an urgent need exists for 
specialist support for earlier diagnosis.
Previous heart failure studies have shown worse 
outcomes for men than women.6,33 Our findings show that 
faster increases in rates of admission to hospital due to 
heart failure and non-cardiovascular disease and slower 
decreases in mortality in women than men has resulted in 
similar outcomes between the sexes over the past decade; 
a finding also reported in Denmark26 and Ontario.28 These 
patterns likely reflect the increasing prevalence of non-
cardiovascular disease comorbidities in women. However, 
the attenuation of sex differences over time, even after 
accounting for comorbidities, and a greater increase in the 
rate of hospitalisations due to heart failure over time in 
women than in men suggest worsening severity of heart 
failure or a lack of effective therapies for heart failure in 
women compared with men. These unfavourable patterns 
in women might also be associated with the increasing 
prevalence of heart failure with preserved ejection fraction 
in women (for which, to date, no proven therapy exists to 
improve outcomes).12,34
The most deprived group had consistently worse 
outcomes than the most affluent group, with 20% 
higher risk of all-cause hospitalisation even after 
adjustment; an inequality that persisted over the past 
20 years. Previously, socioeconomic status has not been 
associated with cause-specific hospitalisation,7 but our 
study highlights a new finding of increased risk across 
all cause-specific outcomes in the most deprived 
patients with heart failure. Although increased burden 
of comorbidities and worse lifestyle risk factors might 
partly explain the increased risk in this group, the 
persisting difference after full adjustment for these 
factors suggests other social and health-care factors 
might be having an effect.35 Potential delays before 
seeking help,36 with increased severity of comorbidities 
and heart failure at the point of diagnosis, might be one 
explanation and points to the preventable nature of 
heart failure. Lower prevalence of cancer in the most 
deprived group than in the most affluent group opposes 
the patterns seen for other comorbidities in our 
population but is perhaps unsurprising considering 
persistent socioeconomic inequalities in cancer 
survival.37
To our knowledge, this is the largest study of incident 
heart failure to report trends in cause-specific hospitalisation 
and mortality in general population groups. By linking 
large, nationally representative databases, we were able to 
ascertain the incident date of heart failure and follow up 
patients for up to 20 years for cause-specific hospitalisation 
and death. However, the use of routinely collected data 
means diagnosis of heart failure can be subject to 
misclassification and measurement error, which might 
change over time. Diagnosis of heart failure in the 
community is clinically defined and we cannot rule out that 
the lower risk of all hospitalisation and mortality outcomes 
in the community-diagnosed group might in part be due to 
misclassification. However, in the UK, diagnosis of heart 
failure has been enhanced by the introduction of 
echocardiography as part of performance incentives38 and 
national heart failure audits and heart failure diagnoses 
have been shown to have high precision in CPRD.17 The 
outcomes measured in this study are also dependent on 
severity or type of heart failure but routine data did not 
provide echocardiographic data or specific heart failure 
phenotypes. To account for severity, a range of comorbidity 
and medications were included in our analyses, but further 
investigation on specific phenotypes of heart failure with 
outcomes is required. Accuracy of clinical recording and 
diagnoses in the CPRD have been found to be valid for a 
range of morbidities16 and we also used primary ICD codes 
for cause-specific outcomes and clinically validated code 
sets, which have high precision.17 Changes in diagnostic 
procedures over time, such as advanced echocardiography 
to detect milder forms of heart failure, might have 
influenced our findings and be partly responsible for the 
small decrease in mortality risk over time. This bias would 
only serve to lessen the overall mortality risk in the later 
time period and stem increasing rates of hospitalisation, 
such that the overall burden of heart failure could be even 
higher than reported here.
Population inequalities in outcomes of heart failure are 
a major and persistent public health challenge. Diverging 
trends among groups suggests that disparities according 
to age, sex, socioeconomic status, and place of diagnosis 
are likely to increase. Tailored management strategies 
that include access to teams specialising in heart failure 
together with social interventions are urgently required 
to address the growing complexity of patients with heart 
failure and decrease the inequitable outcomes of care.
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